Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies
Titel:
Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies
Auteur:
Bérard, F. Giménez-Arnau, A.M. Metz, M. Hide, M. Jain, V. Khemis, A. Lebwohl, M. Palumbo, M. Saini, S. Savk, E. Sussman, G. Szalewski, R. Herniczek, I. Walecka Windom, H. Yang, B. Haemmerle, S. Lheritier, K. Machado, P.G.P. Martzloff, E.D. Seko, N. Wang, P. Zharkov, A. Maurer, M.